While Transmedics Group Inc has overperformed by 5.18%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TMDX fell by -21.01%, with highs and lows ranging from $177.37 to $58.27, whereas the simple moving average fell by -48.12% in the last 200 days.
On December 17, 2024, JP Morgan Downgraded Transmedics Group Inc (NASDAQ: TMDX) to Neutral. A report published by Needham on November 22, 2024, Downgraded its rating to ‘Hold’ for TMDX. Oppenheimer also reiterated TMDX shares as ‘Outperform’, quoting a target price of $125 on the company’s shares in a report dated October 29, 2024. Needham Reiterated the rating as Buy on October 29, 2024, but set its price target from $208 to $109. Robert W. Baird initiated its ‘Outperform’ rating for TMDX, as published in its report on September 24, 2024. Needham’s report from August 21, 2024 suggests a price prediction of $208 for TMDX shares, giving the stock a ‘Buy’ rating. Cantor Fitzgerald also rated the stock as ‘Overweight’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Transmedics Group Inc (TMDX)
Further, the quarter-over-quarter increase in sales is 63.72%, showing a positive trend in the upcoming months.
One of the most important indicators of Transmedics Group Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of 19.41% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.33, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and TMDX is recording 1.73M average volume. On a monthly basis, the volatility of the stock is set at 5.75%, whereas on a weekly basis, it is put at 4.21%, with a loss of -0.48% over the past seven days. Furthermore, long-term investors anticipate a median target price of $102.00, showing growth from the present price of $62.35, which can serve as yet another indication of whether TMDX is worth investing in or should be passed over.
How Do You Analyze Transmedics Group Inc Shares?
The Medical Devices market is dominated by Transmedics Group Inc (TMDX) based in the USA. When comparing Transmedics Group Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 66.80, there is a growth in quarterly earnings of 115.16%.
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.39%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 109.83% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
TMDX shares are owned by institutional investors to the tune of 109.83% at present.
